A vaccine candidate developed by researchers at the University of Oxford has received regulatory approval to begin human clinical trials, marking the first of four vaccines in development to advance to this stage. The trial announcement came eight weeks after a public health emergency declaration related to the Ebola outbreak centered in the Democratic Republic of the Congo.
The outbreak involves the Bundibugyo species of Ebola and has resulted in 625 deaths and 1,792 laboratory-confirmed cases. This particular virus species differs from previously encountered Ebola variants and requires distinct treatment and vaccine approaches. The Oxford team was able to rapidly develop their vaccine candidate by utilizing viral vector technology previously employed in the Covid-19 vaccine program. The technology uses a genetically modified chimpanzee cold virus as a delivery system to introduce a snippet of Ebola genetic material into the body, triggering an immune response without causing actual infection.
The initial trial phase will involve 50 healthy adults aged 18 to 55 in the UK, with monitoring to continue for one year. Researchers are also preparing for subsequent trials in Uganda and other African locations. The Serum Institute of India has manufactured the vaccine to clinical standards and has stockpiled approximately 620,000 doses. Regulatory approval from the UK’s Medicines and Healthcare Products Regulatory Agency followed preclinical testing on mice and macaque monkeys.
Researchers emphasized that while vaccine development normally requires approximately a decade, the current accelerated timeline does not involve cutting corners. Instead, multiple teams are conducting standard testing procedures in parallel across different locations. Scientists acknowledge that the vaccine platform shares a potential rare side effect profile with the previous Oxford Covid vaccine, though they stress such effects remain uncommon and must be weighed against the significantly higher mortality risk posed by Bundibugyo Ebola infection. Three additional vaccine candidates are under development by other organizations, including approaches using mRNA technology and proven methods for related Ebola variants.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI